Exendin-4 vs Adiponectin
Head-to-head comparison of Exendin-4 (Exendin-4 (synthetic exenatide)) and Adiponectin (Adiponectin (Acrp30, AdipoQ)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Exendin-4 | Adiponectin |
|---|---|---|
| Category | Diabetes & Metabolic | Diabetes & Metabolic |
| Full Name | Exendin-4 (synthetic exenatide) | Adiponectin (Acrp30, AdipoQ) |
| Molecular Weight | 4186 Da | ~26.4 kDa (monomer) |
| Half-Life | 2.4 hours | ~2-4 h |
| Amino Acids | 39 | 244 |
| Typical Dose | 5-10 mcg twice daily | No approved human dose; research use only |
| Route | Subcutaneous | IV|SC |
| Purity | ≥98% | ≥98% |
| Studies Count | 1800 | 86 |
| Research Status | Clinical | Pre-clinical |
Exendin-4 Benefits
- ✓beta-cell survival
- ✓glucose-stimulated insulin secretion
- ✓reduced glucolipotoxicity
- ✓lowered HbA1c in clinical use
Adiponectin Benefits
- ✓insulin sensitivity
- ✓fatty-acid oxidation
- ✓AMPK activation
Exendin-4 Dosing
5 mcg SC twice daily for 4 weeks|increase to 10 mcg SC twice daily if tolerated|research: 0.1-1 µM in vitro or 1-10 µg/kg in animals
Adiponectin Dosing
not established|not established
Exendin-4 Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠injection-site reactions
Adiponectin Side Effects
- ⚠unknown
- ⚠immunogenicity risk
Research Overview
Exendin-4
Exendin-4 helped establish GLP-1 receptor biology in diabetes and remains a classic beta-cell protective peptide. Preclinical studies show reduced beta-cell apoptosis, improved insulin content, and better islet function under metabolic stress.
Adiponectin
Preclinical and translational studies link adiponectin signaling with better glycemic control, lower inflammation, and improved lipid handling. Recombinant adiponectin and receptor-targeting approaches remain research tools rather than approved diabetes therapies.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.